Dr. David Kerman, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 190
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Texas Medical School at Houston
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
FL license ME 101537 -
Student in an Organized Health Care Education/Training Program
FL license TRN 9156
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 190
- Services billed
- 340
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 57 | 48 |
| Biopsy of large bowel using a flexible endoscope | 49 | 49 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 41 | 41 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | 28 |
| Established patient office or other outpatient visit, 20-29 minutes | 23 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Miami, FL | 58 |
| Stelara (ustekinumab) | 55 |
| Omeprazole Other prescribers in Miami, FL | 48 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Miami, FL | 43 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Miami, FL | 25 |
| Famotidine Other prescribers in Miami, FL | 25 |
| Mesalamine Other prescribers in Miami, FL | 24 |
| Esomeprazole Magnesium Other prescribers in Miami, FL | 16 |
| Xeljanz (tofacitinib citrate) | 15 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Miami, FL | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $4,433 in total to this clinician.
| Celltrion USA Inc. | $4,350 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $44.55 |
| Lilly USA, LLC | $20.88 |
| Ardelyx, Inc. | $18.01 |
| Consulting Fee | $4,350 |
|---|---|
| Food and Beverage | $83.44 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Celltrion USA Inc. Sep 11, 2025 | Consulting Fee | $4,350 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $128,995 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT06257875 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease
AbbVie Inc. - A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE …
Teva Pharmaceuticals USA, Inc. - Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04075825 - A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Sanofi US Services Inc. · Recruiting · NCT06958536 - M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease
AbbVie Inc. - Vixarelimab ulcerative colitis study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.